Open for inclusion

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Cancer type: Lung cancer, Melanoma

Phase: I/II

Principal Investigator: Hedman Mattias

Country: SE

Keywords: Sweden, Stockholm, BMS986205

Status: Open for inclusion

Link to